메뉴 건너뛰기




Volumn 56, Issue 1, 2011, Pages 164-167

The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth

Author keywords

Neuroblastoma; Phase I; Relapse; Topoisomerase inhibitor

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; FLUDARABINE; GANGLIOSIDE GD2; LINEZOLID; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; QUINOXALINE DERIVATIVE; THYMOCYTE ANTIBODY; TOPOTECAN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; XK 469;

EID: 78649638205     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22639     Document Type: Article
Times cited : (20)

References (12)
  • 1
    • 77956245879 scopus 로고    scopus 로고
    • Phase II randomized comparison of topotecan plus cyclophosphamide vs. topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group Study
    • In press.
    • London WB, Frantz CN, Campbell LA, et al. Phase II randomized comparison of topotecan plus cyclophosphamide vs. topotecan alone in children with recurrent or refractory neuroblastoma: A Children's Oncology Group Study. J Clin Oncol In press.
    • J Clin Oncol
    • London, W.B.1    Frantz, C.N.2    Campbell, L.A.3
  • 2
    • 45849127601 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
    • Stock W, Undevia SD, Bivins C, et al. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs 2008; 26: 331-338.
    • (2008) Invest New Drugs , vol.26 , pp. 331-338
    • Stock, W.1    Undevia, S.D.2    Bivins, C.3
  • 3
    • 33847701595 scopus 로고    scopus 로고
    • Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma
    • Yang Q, Tian Y, Liu S, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007; 67: 1716-1724.
    • (2007) Cancer Res , vol.67 , pp. 1716-1724
    • Yang, Q.1    Tian, Y.2    Liu, S.3
  • 4
    • 0345060436 scopus 로고    scopus 로고
    • Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model
    • Mensah-Osman EJ, Al-Katib AM, Mohammad RM. Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model. Clin Cancer Res 2003; 9: 5794-5797.
    • (2003) Clin Cancer Res , vol.9 , pp. 5794-5797
    • Mensah-Osman, E.J.1    Al-Katib, A.M.2    Mohammad, R.M.3
  • 6
    • 0032742699 scopus 로고    scopus 로고
    • XK469, a selective topoisomerase IIbeta poison
    • Gao H, Huang KC, Yamasaki EF, et al. XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci USA 1999; 96: 12168-12173.
    • (1999) Proc Natl Acad Sci USA , vol.96 , pp. 12168-12173
    • Gao, H.1    Huang, K.C.2    Yamasaki, E.F.3
  • 7
    • 0036131856 scopus 로고    scopus 로고
    • Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination
    • Lin H, Liu XY, Subramanian B, et al. Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. Int J Cancer 2002; 97: 121-128.
    • (2002) Int J Cancer , vol.97 , pp. 121-128
    • Lin, H.1    Liu, X.Y.2    Subramanian, B.3
  • 8
    • 3042749367 scopus 로고    scopus 로고
    • XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways
    • Mensah-Osman E, Al-Katib A, Dandashi M, et al. XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways. Int J Oncol 2003; 23: 1637-1644.
    • (2003) Int J Oncol , vol.23 , pp. 1637-1644
    • Mensah-Osman, E.1    Al-Katib, A.2    Dandashi, M.3
  • 9
    • 33846829572 scopus 로고    scopus 로고
    • The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80
    • Kessel D, Reiners JJ, Jr., Hazeldine ST, et al. The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80. Mol Cancer Ther 2007; 6: 370-379.
    • (2007) Mol Cancer Ther , vol.6 , pp. 370-379
    • Kessel, D.1    Reiners Jr, J.J.2    Hazeldine, S.T.3
  • 10
    • 0035181262 scopus 로고    scopus 로고
    • The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways
    • Ding Z, Parchment RE, LoRusso PM, et al. The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways. Clin Cancer Res 2001; 7: 3336-3342.
    • (2001) Clin Cancer Res , vol.7 , pp. 3336-3342
    • Ding, Z.1    Parchment, R.E.2    LoRusso, P.M.3
  • 11
    • 6544243328 scopus 로고    scopus 로고
    • Preclinical antitumor activity of XK469 (NSC 656889)
    • LoRusso PM, Parchment R, Demchik L, et al. Preclinical antitumor activity of XK469 (NSC 656889). Invest New Drugs 1998; 16: 287-296.
    • (1998) Invest New Drugs , vol.16 , pp. 287-296
    • LoRusso, P.M.1    Parchment, R.2    Demchik, L.3
  • 12
    • 48249135416 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of the quinoxaline antitumour agent R(+)XK469 in patients with advanced solid tumours
    • Undevia SD, Innocenti F, Ramirez J, et al. A phase I and pharmacokinetic study of the quinoxaline antitumour agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer 2008; 44: 1684-1692.
    • (2008) Eur J Cancer , vol.44 , pp. 1684-1692
    • Undevia, S.D.1    Innocenti, F.2    Ramirez, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.